{"CV": [0], "Cardiovascular": [1], "CYP": [2], "Cytochrome": [3], "P": [4], "(CYP)": [5], "Unfractionated": [6], "heparin": [7], "ULN": [8], "Upper": [9], "limit": [10], "of": [11, 24, 76, 84, 141, 149, 180], "normal": [12], "VENTURE-AF": [13], "Active-controlled": [14], "multi-center": [15], "study": [16], "with": [17, 64, 89], "blind-adjudication": [18], "designed": [19], "to": [20, 125], "evaluate": [21], "the": [22, 56, 72, 82, 147], "safety": [23, 75], "uninterrupted": [25, 28], "Rivaroxaban": [26], "and": [27, 59, 67, 74], "vitamin": [29, 176], "K": [30, 47, 163, 177], "antagonists": [31], "in": [32, 62, 87, 115, 128, 136], "subjects": [33], "undergoing": [34], "catheter": [35], "ablation": [36], "for": [37, 81, 94], "non-valvular": [38, 90], "Atrial": [39], "Fibrillation": [40], "VHD": [41], "Valvular": [42], "heart": [43], "disease": [44], "VKA": [45], "Vitamin": [46], "antagonist": [48, 164], "VTE": [49], "Venous": [50], "thromboembolic": [51], "event": [52], "WOEST": [53], "What": [54], "is": [55], "Optimal": [57], "antiplatelet": [58], "anticoagulant": [60], "therapy": [61], "patients": [63, 88, 137], "oral": [65, 79, 165], "anticoagulation": [66], "coronary": [68], "stenting": [69], "X-VeRT": [70], "Explore": [71], "efficacy": [73], "once": [77], "daily": [78], "rivaroxaban": [80], "prevention": [83], "cardiovascular": [85], "events": [86], "atrial": [91, 152], "fibrillation": [92], "scheduled": [93], "cardioversion": [95], "a": [96], "SmPC:": [97], "110": [98], "mg": [99, 134], "BID": [100], "if": [101], "age": [102], ">": [103], "_80": [104], "years,": [105], "concomitant": [106], "verapamil": [107], "(both": [108], "based": [109], "on": [110, 146], "pharmacokinetics/pharmacodynamics": [111], "analyses;": [112], "not": [113], "studied": [114], "this": [116], "setting).b": [117], "Not": [118], "specifically": [119], "studied,": [120], "follow-up": [121], "data": [122], "available": [123], "up": [124], "12": [126], "months": [127], "phase": [129], "III": [130], "trial.c": [131], "SmPc:": [132], "20": [133], "QD": [135], "at": [138], "high": [139], "risk": [140], "recurrence.2021": [142], "EHRA": [143], "Practical": [144], "Guide": [145], "use": [148], "NOACs": [150], "AF,": [151], "fibrillation;": [153], "CrCl,": [154], "creatinine": [155], "clearance;": [156], "INR,": [157], "international": [158], "normalized": [159], "ratio;": [160], "NOAC,": [161], "non-vitamin": [162], "anticoagulant;": [166], "NSAID,": [167], "non-steroidal": [168], "anti-inflammatory": [169], "drug;": [170], "TIA,": [171], "transient": [172], "ischaemic": [173], "attack;": [174], "VKA,": [175], "antagonist.For": [178], "frequency": [179], "visits:": [181], "see": [182], "Figure": [183], "3.": [184]}